Journal article
Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke.
- Montaner J Neurovascular Research Laboratory, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Barcelona, Spain. joan.montaner@vhir.org.
- Ramiro L Neurovascular Research Laboratory, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Simats A Neurovascular Research Laboratory, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Tiedt S Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany.
- Makris K Clinical Biochemistry Department, KAT General Hospital, Kifissia, Athens, Greece.
- Jickling GC Department of Neurology, University of Alberta, Edmonton, AB, Canada.
- Debette S University of Bordeaux, Inserm, Bordeaux Population Health Research Center, team VINTAGE, UMR 1219, Bordeaux, France.
- Sanchez JC Translational Biomarker Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
- Bustamante A Neurovascular Research Laboratory, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Barcelona, Spain.
- 2020-04-24
Published in:
- Nature reviews. Neurology. - 2020
English
Despite many years of research, no biomarkers for stroke are available to use in clinical practice. Progress in high-throughput technologies has provided new opportunities to understand the pathophysiology of this complex disease, and these studies have generated large amounts of data and information at different molecular levels. The integration of these multi-omics data means that thousands of proteins (proteomics), genes (genomics), RNAs (transcriptomics) and metabolites (metabolomics) can be studied simultaneously, revealing interaction networks between the molecular levels. Integrated analysis of multi-omics data will provide useful insight into stroke pathogenesis, identification of therapeutic targets and biomarker discovery. In this Review, we detail current knowledge on the pathology of stroke and the current status of biomarker research in stroke. We summarize how proteomics, metabolomics, transcriptomics and genomics are all contributing to the identification of new candidate biomarkers that could be developed and used in clinical stroke management.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1038/s41582-020-0350-6
- PMID 32322099
- Persistent URL
- https://sonar.ch/global/documents/70233
Statistics
Document views: 18
File downloads: